Using PDCs established from a residual tumor after neoadjuvant chemotherapy from a TNBC patient, the dose-dependent inhibitory effects of KYA1797K were confirmed by decreasing the levels of β-catenin and pan-RAS with ERK and Akt inactivation in TNBC PDCs (Fig. 2a). Here, AKT1 is linked to neoplasm.